Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience

Stereotactic ablative radiotherapy (SABR) has taken a pivotal role in early lung cancer management particularly in the medically inoperable patients. Retrospective studies have shown this to be well tolerated with comparable results to surgery and no significant increase in toxicity. Paucity of rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahya, Sundus, Ghafoor, Qamar, Stevenson, Robert, Watkins, Steven, Allos, Beshar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163903/
https://www.ncbi.nlm.nih.gov/pubmed/30041469
http://dx.doi.org/10.3390/medicines5030077
_version_ 1783359472955031552
author Yahya, Sundus
Ghafoor, Qamar
Stevenson, Robert
Watkins, Steven
Allos, Beshar
author_facet Yahya, Sundus
Ghafoor, Qamar
Stevenson, Robert
Watkins, Steven
Allos, Beshar
author_sort Yahya, Sundus
collection PubMed
description Stereotactic ablative radiotherapy (SABR) has taken a pivotal role in early lung cancer management particularly in the medically inoperable patients. Retrospective studies have shown this to be well tolerated with comparable results to surgery and no significant increase in toxicity. Paucity of randomized evidence has dictated initiation of several trials to provide good quality evidence to steer future practice. This review summaries salient developments in lung SABR, comparisons to surgery and other platforms and our local experience at University Hospitals Birmingham, UK of lung SABR since its initiation in June 2013.
format Online
Article
Text
id pubmed-6163903
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61639032018-10-10 Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience Yahya, Sundus Ghafoor, Qamar Stevenson, Robert Watkins, Steven Allos, Beshar Medicines (Basel) Review Stereotactic ablative radiotherapy (SABR) has taken a pivotal role in early lung cancer management particularly in the medically inoperable patients. Retrospective studies have shown this to be well tolerated with comparable results to surgery and no significant increase in toxicity. Paucity of randomized evidence has dictated initiation of several trials to provide good quality evidence to steer future practice. This review summaries salient developments in lung SABR, comparisons to surgery and other platforms and our local experience at University Hospitals Birmingham, UK of lung SABR since its initiation in June 2013. MDPI 2018-07-23 /pmc/articles/PMC6163903/ /pubmed/30041469 http://dx.doi.org/10.3390/medicines5030077 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yahya, Sundus
Ghafoor, Qamar
Stevenson, Robert
Watkins, Steven
Allos, Beshar
Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title_full Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title_fullStr Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title_full_unstemmed Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title_short Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
title_sort evolution of stereotactic ablative radiotherapy in lung cancer and birmingham’s (uk) experience
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163903/
https://www.ncbi.nlm.nih.gov/pubmed/30041469
http://dx.doi.org/10.3390/medicines5030077
work_keys_str_mv AT yahyasundus evolutionofstereotacticablativeradiotherapyinlungcancerandbirminghamsukexperience
AT ghafoorqamar evolutionofstereotacticablativeradiotherapyinlungcancerandbirminghamsukexperience
AT stevensonrobert evolutionofstereotacticablativeradiotherapyinlungcancerandbirminghamsukexperience
AT watkinssteven evolutionofstereotacticablativeradiotherapyinlungcancerandbirminghamsukexperience
AT allosbeshar evolutionofstereotacticablativeradiotherapyinlungcancerandbirminghamsukexperience

Ejemplares similares